Previously the Diagnostic division of Systagenix, WOUNDCHEK™ Laboratories is focused on the development of novel wound diagnostics products to help improve therapeutic outcomes in wound care. Currently, the cost of ineffective treatment is estimated to be $20-25 billion1Data based on savings calculated with the WOUNDCHEK economic model, UK version, with AQP VLU data inputs. – Nherera L. et al. Quantifying the economic value of diagnostics in wound care in the UK. Poster, EWMA 2013. annually. Clinical experts agree the use of point of care wound diagnostic devices could reduce the cost of ineffective treatment and delayed healing by being able to target the right therapy, on the right patient, at the right time, and for the right length of time²World Union of Wound Healing Societies (WUWHS). Principles of best practice: Diagnostics and wounds. A consensus document. London: MEP Ltd, 2008.. A resulting financial benefit to health care systems can be achieved through significant reduction of the expenses associated with poor targeting of treatment, delayed healing, and avoidable complications. WOUNDCHEK™ Laboratories launched the world’s first and only point of care test to detect EPA (elevated protease activity) in chronic wounds in 2012, and over the past several years has become a recognized leader in wound diagnostics.
The company’s vision is to provide clinicians with better, accurate, timely, actionable, and easy to access information, leading to improved therapeutic outcomes through point of care wound diagnostics. WOUNDCHEK™ Laboratories aims to be the leading and dominant enterprise in wound diagnostics by providing medical professionals with the diagnostic information to:
Identify wounds which are not healing
Intercept issues and early warnings that cause poor wound healing or initiate wounds
Aid in determination of best therapeutic routes
Monitor the effectiveness of a course of treatment
Based in the UK and the USA, WOUNDCHEK™ Laboratories' staff are focused on product development, clinical research, and working with its distribution partners to develop the emerging wound diagnostics markeg.
Our research is centred on two critical questions, identified by clinical experts as primary pieces of diagnostic information needed to direct treatment pathways in the majority of chronic wounds:
WOUNDCHEK™ Protease Status, the world’s first and only point of care test to detect EPA (elevated protease activity), was launched in 2012 and cleared for sale in Europe, the Middle East, South Africa, and Canada.
ISO 9001:2008 and ISO 13485:2003 certified quality management system.